-+ 0.00%
-+ 0.00%
-+ 0.00%

Alphamab Oncology says China NMPA accepts Anbenitamab NDA for neoadjuvant HER2+ breast cancer treatment

PUBT·08/04/2026 10:12:08
Listen to the news
Alphamab Oncology says China NMPA accepts Anbenitamab NDA for neoadjuvant HER2+ breast cancer treatment
  • Alphamab Oncology’s China regulator accepted an NDA for Anbenitamab (KN026) as neoadjuvant therapy for HER2+ early or locally advanced breast cancer.
  • The NMPA placed the filing into its priority review pathway.
  • Application covers use with CSPC’s JMT-Bio unit, pairing Anbenitamab with albumin-bound docetaxel (HB1801).
  • Phase III Neo-Healer study showed 62.4% tpCR, beating trastuzumab plus pertuzumab regimen; one-sided P=0.0036.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12271392), on August 04, 2026, and is solely responsible for the information contained therein.